Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics' stock has been influenced by several key events. In October 2025, the FDA granted Fast Track Designation to AlloNK. In November 2025, the company reported its Third Quarter financial results and presented initial safety and translational data for AlloNK in autoimmune diseases. In January 2026, Artiva announced upcoming presentations at the 2026 Transplantation & Cellular Therapy Meetings. In February 2026, Elaine Sorg was appointed to the Board of Directors, and Thad Huston was appointed as the new CFO. The company also participated in the TD Cowen 46th Annual Health Care Conference in February 2026. In March 2026, Artiva reported its Full Year 2025 financial results and provided updates on the clinical progress of AlloNK. Over the past year, ARTV's stock has traded between $1.47 and $7.75, with a share price of $5.52 as of March 19, 2026, representing a 36.63% increase over the previous year.

Artiva Biotherapeutics does not experience traditional demand seasonality for its products or services. The company's revenue and operational focus are primarily driven by research and development milestones, clinical trial progress, and regulatory approvals, rather than seasonal consumer demand for commercialized products.

Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers, creating "off-the-shelf" allogeneic NK cell therapies derived from donor cells that are pre-manufactured and stored frozen for immediate use. Its major product candidates include AlloNK (AB-101) for autoimmune diseases and B-cell non-Hodgkin lymphoma, AB-201 for solid tumors, and AB-205 for hematological malignancies. AlloNK has received FDA Fast Track Designation for refractory rheumatoid arthritis in combination with rituximab.

Artiva Biotherapeutics is headquartered in San Diego, California, with R&D and GMP manufacturing facilities. The company also utilizes the capabilities of its partner, GC Cell, which has a cell center in the Republic of Korea.

Artiva Biotherapeutics generally holds a positive brand reputation, particularly within the analyst community, with a consensus rating of "Moderate Buy" or "Strong Buy". This positive sentiment is supported by promising clinical developments, such as the positive initial safety and translational data for AlloNK in autoimmune diseases. The company's mission to develop effective, safe, and accessible cell therapies for devastating autoimmune diseases and cancers also contributes to its reputation. There have been no significant negative events impacting its brand reputation reported in the past year.

Artiva Biotherapeutics has a diverse ownership structure with 37 institutional owners and shareholders holding 17,178,993 shares. Major institutional owners include RA Capital Management, L.P., 5AM Venture Management, LLC, VR Adviser, LLC, venBio Partners LLC, Franklin Resources Inc, Revelation Capital Management, LLC, Vanguard Group Inc, Millennium Management Llc, BlackRock, Inc., and Wellington Management Group Llp. The ownership breakdown is VC/PE Firms at 55.9%, Public Companies at 18.5%, Institutions at 13.1%, Individual Insiders at 8.5%, and General Public at 4.04%.